When was Elastagen founded?

Elastagen was founded in 2003 and raised its 1st funding round 2 years after it was founded.

Where is Elastagen located?

Elastagen is headquartered in Sydney, Australia.

How many employees does Elastagen have?

As of Jul 01, 2024, the latest employee count at Elastagen is 2.

Is Elastagen a funded company?

Elastagen is a funded company, having raised a total of $14.7M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2005.

When was the latest funding round of Elastagen?

Elastagen's latest funding was a $***** Grant (prize money) round on Oct 11, 2016, with participation from 0 investor.

Where does Elastagen rank among its competitors?

Elastagen ranks 287th amongst 1947 active competitors, of which 454 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Elastagen?

Elastagen's top competitors include Synthego, Sutro Biopharma and Korro Bio. Among them, Antheia secured the most recent funding round in January, 2026.

Elastagen - 2026 Company Profile, Funding & Competitors

Q: Is Elastagen an acquired company?

Elastagen got acquired by Allergan on Feb 07, 2018.

Elastagen is an acquired company based in Sydney (Australia), founded in 2003. It operates as a Company offering solutions for cell growth and tissue repair through their Elastin technology. Elastagen has raised $14.7M in funding from investors like Wellcome Trust, AmorePacific and Korea Investment Holdings. The company has 1947 active competitors, including 454 funded and 347 that have exited. Its top competitors include companies like Synthego, Sutro Biopharma and Korro Bio.

Company Details

Elastagen is a clinical stage medical company with a pipeline of formulation products based on the human protein tropoelastin.The company was founded after the acquisition of the Elastin technology from its founding scientist Prof Weiss (who is also the company's Lead Scientific Advisor) and his team at the University of Sydney. The Elastin technology offers a new pathway to produce a synthetic, identical and recombinant version of the naturally found "tropoelastin", the building blocks of elastin, a critical component in tissues responsible for the ability of lungs, skin, arteries and other elastic ligaments to stretch and recoil. The company claims that it is the first and only provider of commercial cGMP clinical grade human tropoelastin which can be used to support cell growth and tissue repair. Elastagen also claims the recombinant tropoelastin has an ideal biocompatibility profile and no immune rejection problems. Currently, the company is conducting pivotal clinical studies an injectable dermo-aesthetic product that supposedly restores the elasticity of the skin. In addition, it is investigating solutions for Atrophic Scars, Scar Revision and wound healing. Elastagen claims that its technology has potential applications in skin rejuvenation, scar remodelling and tissue repair. The company also has operations in Europe and UK.

Website: elastagen.com
Social
Email ID: *****@elastogen.com

Key Metrics

Founded Year

2003

Location

Sydney, Australia

Stage

Acquired

Total Funding

$14.7M in 6 rounds

Latest Funding Round

Grant (prize money), Oct 11, 2016, $*****

Investors

Wellcome Trust & 8 more

Ranked

287^th among 1947 active competitors

Employee Count

2 as on Jul 01, 2024

Similar Companies

Synthego & 2658 more

Exit Details

Acquired by Allergan (Feb 07, 2018)

View Elastagen's full profile

Elastagen got acquired by Allergan on Feb 07, 2018 at an acquisition amount of $*****.

Click here to take a look at Elastagen's acquisition in detail

Elastagen has raised a total funding of $14.7M over 6 rounds. Its first funding round was on 2005. Elastagen has 9 institutional investors.

Here is the list of recent funding rounds of Elastagen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 11, 2016	3972069	Grant (prize money)	9780786	2262196	6759583	9983858
Jun 21, 2016	9546601	Series B	2302349	9991876	2666295	Cell Innovation Partners
Jan 07, 2016	4351934	Series B	2566268	4418162	Wellcome Trust & 2 more	GBS & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Elastagen's funding rounds and investors

Elastagen's employee count trend

Elastagen has 2 employees as of Jul 24. Here is Elastagen's employee count trend over the years:

Uncover Elastagen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Elastagen include Synthego, Sutro Biopharma and Korro Bio. Here is the list of Top 10 competitors of Elastagen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, Perceptive Advisors & 30 others	71/100
2nd	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	69/100
3rd	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Citadel, Point72 & 14 others	67/100
4th	Avidity Biosciences 2012, San Diego (United States), Acquired	RNA therapeutics innovator targeting muscle and other diseases with AOC platform	$143M	RTW Investments, Takeda Ventures & 19 others	67/100
5th	Savara Pharma 2008, Austin (United States), Public	Developer of therapeutics for rare respiratory diseases	$67.8M	Austin Technology Incubator, Logos & 19 others	67/100
6th	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
7th	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, China Structural Reform Fund ... & 11 others	66/100
8th	Invenra 2011, Madison (United States), Series A	Pioneering bispecific and trispecific antibody discovery and development for novel therapies	$21.3M	Venture Investors, Venture Management & 4 others	65/100
9th	Judges Scientific 2002, London (United Kingdom), Public	Acquisition and development of scientific instrument businesses	-	Origin Capital, Lloyds Banking Group	65/100
10th	Checkerspot 2016, Oakland (United States), Series C	Novel materials for various applications using synthetic biology	$117M	ArrowMark Partners, Viking Global Investors ... & 15 others	65/100
287th	Elastagen 2003, Sydney (Australia), Acquired	Company offering solutions for cell growth and tissue repair through their Elastin technology	$14.7M	GBS, ATP-Innovations & 7 others	40/100